ライフサイエンスコーパス: complement activity

1 in the expression of proteins essential for complement activity.

2 eminate through body fluids that are rich in complement activity.

3 ecial emphasis on their capacity to modulate complement activity.

4 model and sensitizes P. aeruginosa to serum complement activity.

5 ease, cobra venom factor was used to deplete complement activity.

6 architecture as MBL but lacks any intrinsic complement activity.

7 ly in the thymus, because of low intrathymic complement activity.

8 ions and purified CP both suppress hemolytic complement activity.

9 ignificantly affect systemic levels of serum complement activity.

10 ral health was found to lack serum hemolytic complement activity.

11 nent in cartilage, as well as a regulator of complement activity.

12 eceptor 1 (CR1) is involved in regulation of complement activity.

13 zed for phagocytosis by nonimmune serum with complement activity.

14 laevis resulted in significant inhibition of complement activities.

15 S. aureus mechanism for modification of host complement activities.

16 ement, whereas anti-CsMAP34 antibody blocked complement activities.

17 lone; the COG3236 domain was unnecessary for complementing activity.

18 amma-tubulin ring complex and the centrosome-complementing activity.

19 reas removing the gamma-tubulin destroys the complementing activity.

20 is indicated that only APT1 could code for a complementing activity.

21 buffer containing 0.4 M KCl eluted only the complementing activity.

22 itro in the absence of exogenous apobec-1 or complementing activity.

23 ignificantly affect systemic levels of serum complement activity, a potential benefit for stroke pati

24 tration of eculizumab, at doses that blocked complement activity, aborted acute progressive thromboti

25 TP10 significantly inhibited complement activity after 10 to 15 minutes of CPB and th

26 ipients displayed > 90% inhibition of plasma complement activity and a marked reduction in tissue C3

27 We measured complement activity and ADAMTS13 function, and completed

28 In the present case-control study, complement activity and concentrations of complement com

29 imab to human CD20(+) cells leads to loss of complement activity and consumption of component C2.

30 that in combination have dramatic effects on complement activity and disease risk.

31 n the clinic because of the presence of high complement activity and high anti-Gal Ab titers in human

32 tramers are the most efficient at increasing complement activity and PGA formation.

33 njury was associated with a decline in serum complement activity and progressive intrapulmonary seque

34 tural antibody with a lesser contribution of complement activity and the presence of neutrophils.

35 Crry-Ig, had no significant effect on serum complement activity at minimum effective therapeutic dos

36 doses > or =1 mg/kg, significantly inhibits complement activity at the levels of C3 and C5 in patien

37 NA affinity chromatography, we show that the complementing activity binds to a 280-nucleotide apo-B R

38 ively with fibrinolysis, pexelizumab blocked complement activity but reduced neither infarct size by

39 dose-dependent manner and that Efb inhibits complement activity by blocking deposition of C3 or by p

40 Serum complement activity (CH(50)) in severe and mild EAMG was

41 The highly enriched complementing activity copurified with a DNA polymerase,

42 In contrast, pneumolysin's complement activity correlated with bacterial growth and

43 Complementing activity could be isolated from PICs, and

44 for each disease, therapeutic modulation of complement activity emerges as an attractive target for

45 rying degrees, whereas ATPase mutants had no complementing activity, even when the mutant protein was

46 -1 immobilized on beads depleted >90% of the complementing activity from partially purified extracts.

47 the anti-donor IgM Ab level was maximal and complement activity had returned to approximately 50% of

48 LL NUMBER REGULATOR13 (CNR13), the maize MID-COMPLEMENTING ACTIVITY homolog.

49 Cobra venom factor completely inhibited complement activity in four (group 2) and dextran sulfat

50 method for assay of lectin pathway-mediated complement activity in human serum that should be useful

51 aluated by the inhibition of total hemolytic complement activity in human serum.

52 ddition, AMD is not associated with systemic complement activity in LT patients.

53 atour et al describe ex vivo measurements of complement activity in paroxysmal nocturnal hemoglobinur

54 human properdin to restore LPS-dependent AP complement activity in properdin-/- mouse serum correlat

55 Many older reports indicate altered serum complement activity in schizophrenia, though the data ar

56 Complement activity in the baboons was within the normal

57 These results implicate excessive complement activity in the development of schizophrenia

58 t the C-terminal region of Efb could inhibit complement activity in vitro.

59 ent S. aureus infections by interfering with complement activity in vivo.

60 1 were not required for interaction with the complementing activity in vitro.

61 DExx region, and the SRC region, inactivated complementing activity in vivo and clamp loading in vitr

62 of S. cerevisiae SEC65 and tested these for complementing activity in vivo and for SRP integrity in

63 utant gene, on a multicopy plasmid, retained complementing activity in vivo and the mutant gene also

64 However, pneumolysin's complement activity inhibited killing of mutant bacteria

65 clusion, our data corroborate that hemolytic complement activity is essential for control of bacterem

66 Furthermore, novel complement activity is introduced concurrently with MASP

67 hese findings suggest that local intraocular complement activity is of greater importance in AMD path

68 The data reveal that complement activity is remarkably tolerant to changes in

69 nction of these additional factors, known as complementing activity, is not known.

70 Thus, both pneumolysin's hemolytic and complement activities made specific contributions to the

71 tion, the observed CP-mediated inhibition of complement activity may contribute to the lack of inflam

72 Our results suggest that the complementing activity may function as the RNA-binding s

73 geted channel mutants as well as double mid1-complementing activity (MCA) channel mutants did not aff

74 Inhibition of complement activity, measured by CH50, was significant f

75 2 cells was expressed transiently, with peak complementing activity observed when cells were treated

76 n and a more potent anti-alternative pathway complement activity of Crry contributed to its indispens

77 The antiserum inhibited hemolytic complement activity of Lewis (RT1(1)) rats in vivo and i

78 combinant PKF, which was shown to reduce the complement activity of normal human serum by almost 50%.

79 The complement activity of the perfusate was reduced by CAB-

80 elevated apoptotic threshold, modulation of complement activity or diminished cellular cytotoxicity.

81 the N-glycan structures could activate serum complement activity, possibly by the lectin pathway of c

82 Basal complement activity presents a potential danger for "sel

83 The ubiquitous protein CD46, a regulator of complement activity, promotes T cell activation and diff

84 cobra venom factor, which depleted serum of complement activity, protected mice from AAA development

85 ycoprotein that belongs to the regulators of complement activity (RCA) family.

86 m whether the incorporation of regulators of complement activity (RCA) into the viral envelope afford

87 Deletion analysis localized the complementing activity (Rej) to the putative Env signal

88 absence of either pneumolysin's hemolytic or complement activities rendered mutant strains less virul

89 DNA sequence analysis revealed that the complementing activity resulted from a single point muta

90 To assess the effect of treatment on complement activity, sera from dosed subjects were analy

91 advanced the concept that subtle changes in complement activity significantly affect disease risk.

92 ic ("hemolytic") and complement-activation ("complement") activities that have been mapped to several

93 rome (aHUS) is characterized by dysregulated complement activity, the development of a thrombotic mic

94 SP-A may down-regulate complement activity through its association with C1q.

95 g and complementation analysis localized the complementing activity to a 2.8-kb B. pertussis genomic

96 e studied soluble CR1, a potent regulator of complement activity, to test whether it restores complem

97 Systemic complement activity was ascertained by measuring levels

98 Pneumolysin's complement activity was not associated with the degree o

99 n of the two polypeptides with transcription-complementing activity was confirmed with specific antib

100 ional holoenzyme containing apobec-1 and the complementing activity was eluted from the apobec-1-affi

101 The complementing activity was identified as HMGB1 (the high

102 The complementing activity was protease-sensitive and microc

103 Complementing activity was reduced when HumD was express

104 in the cytokine milieu, induced by a loss of complement activity, were found to alter prosurvival sig

105 hen assayed individually, were found to have complementing activity when co-expressed together.

106 Fractionation of the complementing activity yielded HMG I(Y), a nonhistone ch

107 Isolation of the intermolecular integration-complementing activity yielded HMG I(Y), as in the HIV-1